Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 401-406

  Ko, Eunkyung ^a   Kim, Yujin ^a   Park, Seong Eun ^a   Cho, Eun Yoon ^a   Han, Jungho ^a   Shim, Young Mog ^a   Park, Joobae ^a   Kim, Duk Hwan ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cyclin D1; Cyclin D2; Heterogeneity; Immunohistochemistry; Non small cell lung cancer; Recurrence

Indexed keywords

CISPLATIN; CYCLIN D1; CYCLIN D2; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUESTIONNAIRE; RECURRENT CANCER; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN D1; CYCLIN D2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; RECURRENCE; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863780346     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.027     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. International adjuvant lung cancer trial collaborative group: cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
3. Strauss G.M., Herndon J.E., Maddaus M.A., Johnstone D.W., Johnson E.A., Harpole D.H., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008, 26:5043-5051.
4. Pepe C., Hasan B., Winton T.L., Seymour L., Graham B., Livingston R.B., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007, 25:1553-1561.
5. Takano Y., Kato Y., Masuda M., Ohshima Y., Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol 1999, 189:194-200.
6. Sicinski P., Donaher J.L., Geng Y., Parker S.B., Gardner H., Park M.Y., et al. Cyclin D2 is an FSH responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996, 384:470-474.
7. Sasaki Y., Jensen C.T., Karlsson S., Jacobsen S.E. Enforced expression of cyclin D2 enhances the proliferative potential of myeloid progenitors, accelerates in vivo myeloid reconstitution, and promotes rescue of mice from lethal myeloablation. Blood 2004, 104:986-992.
8. Jena N., Deng M., Sicinska E., Sicinski P., Daley G.Q. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res 2002, 62:535-541.
9. Yu J., Leung W.K., Ebert M.P., Leong R.W., Tse P.C., Chan M.W., et al. Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer 2003, 88:1560-1565.
10. Nacht M., Ferguson A.T., Zhang W., Petroziello J.M., Cook B.P., Gao Y.H., et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999, 59:5464-5470.
11. Evron E., Umbricht C.B., Korz D., Raman V., Loeb D.M., Niranjan B., et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001, 61:2782-2787.
12. Henrique R., Costa V.L., Cerveira N., Carvalho A.L., Hoque M.O., Ribeiro F.R., et al. Hypermethylation of cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med 2006, 84:911-918.
13. Virmani A., Rathi A., Heda S., Sugio K., Lewis C., Tonk V., et al. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer 2003, 107:341-345.
14. Lehmann U., Länger F., Feist H., Glöckner S., Hasemeier B., Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002, 160:605-612.
15. Padar A., Sathyanarayana U.G., Suzuki M., Maruyama R., Hsieh J.T., Frenkel E.P., et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res 2003, 9:4730-4734.
16. Sinclair A.J., Palmero I., Holder A., Peters G., Farrell P.J. Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol 1995, 69:1292-1295.
17. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. American Joint Committee on Cancer: AJCC Cancer Staging Manual 2002, Springer, New York, p. 167-81. 6th ed.
18. Kim J.S., Kim J.W., Han J., Shim Y.M., Park J., Kim D.H. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006, 66:4049-4054.
19. Ko E., Park S.E., Cho E.Y., Kim Y., Hwang J.A., Lee Y.S., et al. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Breast Cancer Res 2010, 12:R100.
20. Bouchard C., Thieke K., Maier A., Saffrich R., Hanley-Hyde J., Ansorge W., et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999, 19:5321-5333.
21. Susaki E., Nakayama K., Nakayama K.I. Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition. Mol Cell Biol 2007, 27:4626-4640.
22. Meyyappan M., Wong H., Hull C., Riabowol K.T. Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Mol Cell Biol 1998, 18:3163-3172.
23. Chen B., Pollard J.W. Cyclin D2 compensates for the loss of cyclin D1 in estrogen-induced mouse uterine epithelial cell proliferation. Mol Endocrinol 2003, 17:1368-1381.
24. Fantl V., Stamp G., Andrews A., Rosewell I., Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995, 9:2364-2372.
25. Sicinski P., Donaher J.L., Parker S.B., Li T., Fazeli A., Gardner H., et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995, 82:621-630.
26. Carthon B.C., Neumann C.A., Das M., Pawlyk B., Li T., Geng Y., et al. Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol 2005, 25:1081-1088.
27. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
28. Mitra R., Lee J., Jo J., Milani M., McClintick J.N., Edenberg H.J., et al. Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clin Cancer Res 2011, 17:2934-2946.